Hepatitis B Virus X Protein Promotes the Stem-like Properties of OV6 Cancer Cells in Hepatocellular Carcinoma

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2017 Jan 20

PMID 28102846

Citations 30

Authors

Chao Wang

Ming-Da Wang

Peng Cheng

Hai Huang

Wei Dong

Wei-Wei Zhang

Peng-Peng Li

Chuan Lin

Ze-Ya Pan

Meng-Chao Wu

Wei-Ping Zhou

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus X protein (HBx) and cancer stem-like cells (CSCs) have both been implicated in the occurrence and development of HBV-related hepatocellular carcinoma (HCC). However, whether HBx contributes to the stem-like properties of OV6 CSCs in HCC remains elusive. In this study, we showed that the concomitant expression of HBx and OV6 was closely associated with the clinical outcomes and prognosis of patients with HBV-related HCC. HBx was required for the stem-like properties of OV6 liver CSCs, including self-renewal, stem cell-associated gene expression, tumorigenicity and chemoresistance. Mechanistically, HBx enhanced expression of MDM2 by directly binding with MDM2 and inhibiting its ubiquitin-directed self-degradation. MDM2 translocation into the nucleus was also upregulated by HBx and resulted in enhanced transcriptional activity and expression of CXCL12 and CXCR4 independent of p53. This change in expression activated the Wnt/β-catenin pathway and promoted the stem-like properties of OV6 liver CSCs. Furthermore, we observed that the expression of any two indicators from the HBx/MDM2/CXCR4/OV6 axis in HCC biopsies could predict the prognosis of patients with HBV-related HCC. Taken together, our findings indicate the functional role of HBx in regulating the stem-like properties of OV6 CSCs in HCC through the MDM2/CXCL12/CXCR4/β-catenin signaling axis, and identify HBx, MDM2, CXCR4 and OV6 as a novel prognostic pathway and potential therapeutic targets for patients with HBV-related HCC patients.

Citing Articles

Insight into the mechanisms regulating liver cancer stem cells by hepatitis B virus X protein.

Li X, Kong D, Hu W, Zheng K, You H, Tang R Infect Agent Cancer. 2024; 19(1):56.

PMID: 39529119 PMC: 11555838. DOI: 10.1186/s13027-024-00618-y.

Radiofrequency ablation: mechanisms and clinical applications.

Wu J, Zhou Z, Huang Y, Deng X, Zheng S, He S MedComm (2020). 2024; 5(10):e746.

PMID: 39359691 PMC: 11445673. DOI: 10.1002/mco2.746.

Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.

Zhang Q, Tsui Y, Zhang V, Lu A, Lee J, Lee E Theranostics. 2024; 14(2):892-910.

PMID: 38169544 PMC: 10758064. DOI: 10.7150/thno.87962.

Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.

Amin M, El-Far Y, El-Mowafy M, Elgaml A Clin Epigenetics. 2023; 15(1):180.

PMID: 37941056 PMC: 10634085. DOI: 10.1186/s13148-023-01593-8.

Integrated analysis of intratumoral biomarker and tumor-associated macrophage to improve the prognosis prediction in cancer patients.

Wang M, Xiang H, Hong T, Mierxiati A, Yan F, Zhang L BMC Cancer. 2023; 23(1):593.

PMID: 37370037 PMC: 10294501. DOI: 10.1186/s12885-023-11027-6.

References

Lau E, Lo J, Cheng B, Ma M, Lee J, Ng J . Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Cell Rep. 2016; 15(6):1175-89. DOI: 10.1016/j.celrep.2016.04.019. View

Wade M, Wang Y, Wahl G . The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010; 20(5):299-309. PMC: 2910097. DOI: 10.1016/j.tcb.2010.01.009. View

Fan H, Zhang H, Pascuzzi P, Andrisani O . Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene. 2015; 35(6):715-26. PMC: 4615262. DOI: 10.1038/onc.2015.122. View

Dolma S, Selvadurai H, Lan X, Lee L, Kushida M, Voisin V . Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell. 2016; 29(6):859-873. PMC: 5968455. DOI: 10.1016/j.ccell.2016.05.002. View

Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y . CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013; 152(5):1077-90. PMC: 3594500. DOI: 10.1016/j.cell.2013.01.053. View

Kaindl U, Morak M, Portsmouth C, Mecklenbrauker A, Kauer M, Zeginigg M . Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia. 2013; 28(3):600-8. PMC: 3948158. DOI: 10.1038/leu.2013.345. View

Lu W, Bird T, Boulter L, Tsuchiya A, Cole A, Hay T . Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat Cell Biol. 2015; 17(8):971-983. PMC: 4612439. DOI: 10.1038/ncb3203. View

Guo Z, Jiang J, Zhang J, Yang H, Yang F, Qi Y . COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells. Medicine (Baltimore). 2015; 94(44):e1806. PMC: 4915881. DOI: 10.1097/MD.0000000000001806. View

Arzumanyan A, Friedman T, Ng I, Clayton M, Lian Z, Feitelson M . Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?. Cancer Res. 2011; 71(10):3701-8. PMC: 3096741. DOI: 10.1158/0008-5472.CAN-10-3951. View

10.

Su C, Lin Y, Cai L, Mao Q, Niu J . Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study. Sci Rep. 2016; 6:32147. PMC: 4997250. DOI: 10.1038/srep32147. View

11.

Chiba T, Kamiya A, Yokosuka O, Iwama A . Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett. 2009; 286(2):145-53. DOI: 10.1016/j.canlet.2009.04.027. View

12.

Wen W, Ding J, Sun W, Fu J, Chen Y, Wu K . Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. Hepatology. 2012; 55(6):1787-98. DOI: 10.1002/hep.25596. View

13.

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Minden M . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8. DOI: 10.1038/367645a0. View

14.

Zhang F, Throm S, Murley L, Miller L, Steven Zatechka Jr D, Guy R . MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol. 2011; 82(1):24-34. PMC: 3108438. DOI: 10.1016/j.bcp.2011.03.024. View

15.

Guan D, Shi J, Zhang Y, Zhao J, Long L, Chen T . Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology. 2015; 62(6):1791-803. DOI: 10.1002/hep.28117. View

16.

Ning B, Ding J, Yin C, Zhong W, Wu K, Zeng X . Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res. 2010; 70(19):7640-51. DOI: 10.1158/0008-5472.CAN-10-0824. View

17.

Yang W, Wang C, Lin Y, Liu Q, Yu L, Yan H . OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol. 2012; 57(3):613-20. DOI: 10.1016/j.jhep.2012.04.024. View

18.

Chen H, Kuo T, Tseng C, Ma J, Yang S, Yen C . Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology. 2016; 64(5):1637-1651. DOI: 10.1002/hep.28773. View

19.

Shahbazi Azar S, Mansoori M, Attar M, Shahbazi M . Tumor Necrosis Factor Alpha 308 G/A Single Nucleotide Polymorphism and Susceptibility to Hepatocellular Carcinoma Via Hepatitis B Infection. Asian Pac J Cancer Prev. 2016; 17(7):3381-4. View

20.

Pang Y, Zhong J, Luo X, Ou C, Guo Z, Xiang B . Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi. Tumour Biol. 2015; 37(5):5879-84. DOI: 10.1007/s13277-015-4446-3. View